Autoantibodies that recognize a complex of β2-glycoprotein I (β2GPI) and HLA-DR were associated with recurrent pregnancy loss in a Japanese multi-centre cross-sectional study. Of the 227 women with recurrent pregnancy loss included in the study, 52 (22.9%) were positive for anti-β2GPI–HLA-DR antibodies. By contrast, only 45 (19.8%) were positive for at least one of the five antiphospholipid antibodies (aPL) required for a classification of antiphospholipid syndrome (APS). Furthermore, of the 112 women in the study who had clinical manifestations of APS but were negative for classification criteria aPL, 21 (18.8%) were positive for anti-β2GPI–HLA-DR antibodies.
References
Original article
Tanimura, K. et al. The β2-glycoprotein I/HLA-DR complex is the major autoantibody target in obstetric antiphospholipid syndrome. Arthritis Rheumatol. https://doi.org/10.1002/art.41410 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Clarke, J. β2GPI–HLA-DR linked to recurrent pregnancy loss. Nat Rev Rheumatol 16, 472 (2020). https://doi.org/10.1038/s41584-020-0475-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-0475-4
